Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy

Saaya Yoshida, Taku Fujimura, Yumi Kambayashi, Ryo Amagai, Akira Hashimoto, Setsuya Aiba

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

Nivolumab plus ipilimumab combined therapy is one of the promising drugs that enhance the anti- immune response in patients with advanced melanoma. Therefore, to increase its response rate is of great interest to dermatologists. Recent reports suggested that, since CD8+ T cells after the administration of ICIs increase the RANKL expression to induce an immunosuppressive tumor microenvironment in melanoma, denosumab might enhance the anti-tumor effects of immune checkpoint inhibitors, such as nivolumab and ipilimumab. In this report, we present a case of multiple metastatic melanoma with nivolumab, ipilimumab plus denosumab combined therapy.

Original languageEnglish
Pages (from-to)829-833
Number of pages5
JournalCase Reports in Oncology
Volume12
Issue number3
DOIs
Publication statusPublished - 2019 Sep 1

Keywords

  • Advanced melanoma
  • Bone metastasis
  • Denosumab
  • Nivolumab plus ipilimumab combined therapy
  • RANKL

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy'. Together they form a unique fingerprint.

Cite this